Edition:
United States

Catalyst Biosciences Inc (CBIO.OQ)

CBIO.OQ on NASDAQ Stock Exchange Capital Market

10.52USD
22 Jun 2018
Change (% chg)

$0.15 (+1.45%)
Prev Close
$10.37
Open
$10.44
Day's High
$10.58
Day's Low
$10.26
Volume
1,115,167
Avg. Vol
106,823
52-wk High
$37.00
52-wk Low
$3.13

Select another date:

Thu, May 3 2018

BRIEF-Catalyst Biosciences Reports Q1 Loss Per Share $0.56

* CATALYST BIOSCIENCES REPORTS FIRST QUARTER OPERATING & FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Catalyst Biosciences Receives $1.5 Million For Neuronal Nicotinic Receptor Asset

* CATALYST BIOSCIENCES RECEIVES $1.5 MILLION IN TWO MILESTONE PAYMENTS FOR NEURONAL NICOTINIC RECEPTOR (NNR) ASSET Source text for Eikon: Further company coverage:

BRIEF-Catalyst Biosciences Provides Corporate Update

* CATALYST BIOSCIENCES REPORTS FOURTH QUARTER AND FULL-YEAR 2017 OPERATING & FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Catalyst Biosciences Announces Manufacturing Agreement With AGC Biologics For Subcutaneous Factor IX Product CB 2679D

* CATALYST BIOSCIENCES ANNOUNCES MANUFACTURING AGREEMENT WITH AGC BIOLOGICS FOR SUBCUTANEOUS FACTOR IX PRODUCT CB 2679D

BRIEF-Catalyst Biosciences Says Public Offering Of 2.94 Mln Common Shares Priced At $34/Share

* CATALYST BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Catalyst Biosciences Announces Proposed Public Offering Of Common Stock

* CATALYST BIOSCIENCES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-RTW Investments Reports A 5.71 Percent Passive Stake In Catalyst Biosciences

* RTW INVESTMENTS, LP REPORTS A 5.71 PERCENT PASSIVE STAKE IN CATALYST BIOSCIENCES AS OF JAN 26, 2018 Source text: (http://bit.ly/2nDJSqt) Further company coverage:

BRIEF-Catalyst Biosciences Files For Mixed Shelf Of Up To $150 Mln

* CATALYST BIOSCIENCES INC FILES FOR MIXED SHELF OF UP TO $150 MILLION - SEC FILING Source text - http://bit.ly/2F2CQC6 Further company coverage:

BRIEF-Catalyst Biosciences Initiates Phase 2/3 Trial Of Marzeptacog Alfa (Activated)

* CATALYST BIOSCIENCES INITIATES PHASE 2/3 TRIAL OF MARZEPTACOG ALFA (ACTIVATED) FOR PROPHYLAXIS IN HEMOPHILIA A OR B WITH INHIBITORS

BRIEF-Nexthera Capital Reports 5.4 Pct Passive Stake In Catalyst Biosciences

* NEXTHERA CAPITAL REPORTS A 5.4 PERCENT PASSIVE STAKE IN CATALYST BIOSCIENCES AS OF DEC 20 - SEC FILING Source text : (http://bit.ly/2l9OsLV) Further company coverage:

Select another date: